APA (7th ed.) Citation

Shah, N. P., García-Gutiérrez, V., Jiménez-Velasco, A., Larson, S., Saussele, S., Rea, D., . . . Lipton, J. H. (2020). Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: The DASFREE study. Leukemia & Lymphoma, 61(3), 650. https://doi.org/10.1080/10428194.2019.1675879

Chicago Style (17th ed.) Citation

Shah, Neil P., et al. "Dasatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia and Stable Deep Molecular Response: The DASFREE Study." Leukemia & Lymphoma 61, no. 3 (2020): 650. https://doi.org/10.1080/10428194.2019.1675879.

MLA (9th ed.) Citation

Shah, Neil P., et al. "Dasatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia and Stable Deep Molecular Response: The DASFREE Study." Leukemia & Lymphoma, vol. 61, no. 3, 2020, p. 650, https://doi.org/10.1080/10428194.2019.1675879.